Wells Fargo & Company Biomarin Pharmaceutical Inc Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Wells Fargo & Company holds 57,943 shares of BMRN stock, worth $4.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,943

Previous 65,085 10.97%

Holding current value

$4.17 Million

Previous $4.57 Million 16.75%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$61.93 - $70.49 $442,304 - $503,439	-7,142 Reduced 10.97%	57,943 $3.81 Million
Q3 2024 Nov 13, 2024	SELL	$69.02 - $93.84 $4.77 Million - $6.48 Million	-69,081 Reduced 51.49%	65,085 $4.57 Million
Q2 2024 Aug 13, 2024	SELL	$74.43 - $92.22 $20.1 Million - $24.9 Million	-270,400 Reduced 66.84%	134,166 $11 Million
Q1 2024 May 10, 2024	BUY	$83.81 - $99.0 $16.3 Million - $19.3 Million	195,003 Added 93.05%	404,566 $35.3 Million
Q4 2023 Feb 09, 2024	SELL	$76.22 - $98.51 $2.99 Million - $3.87 Million	-39,267 Reduced 15.78%	209,563 $20.2 Million
Q3 2023 Nov 13, 2023	BUY	$85.07 - $94.48 $697,914 - $775,113	8,204 Added 3.41%	248,830 $22 Million
Q2 2023 Aug 15, 2023	SELL	$86.68 - $100.3 $8.94 Million - $10.3 Million	-103,088 Reduced 29.99%	240,626 $20.9 Million
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $562,062 - $751,231	-6,406 Reduced 1.83%	343,714 $33.4 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $217,297 - $291,671	2,685 Added 0.77%	350,120 $36.2 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $1.47 Million - $1.74 Million	17,932 Added 5.44%	347,435 $29.5 Million
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $1.8 Million - $2.19 Million	-25,224 Reduced 7.11%	329,503 $27.3 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $4.33 Million - $5.41 Million	58,349 Added 19.69%	354,727 $27.4 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $4.49 Million - $5.73 Million	62,642 Added 26.8%	296,378 $26.2 Million
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $1.81 Million - $2.07 Million	-24,227 Reduced 9.39%	233,736 $18.1 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $5.8 Million - $6.51 Million	-76,787 Reduced 22.94%	257,963 $21.5 Million
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $16.1 Million - $19.5 Million	-214,799 Reduced 39.09%	334,750 $25.3 Million
Q4 2020 Feb 09, 2021	BUY	$72.61 - $90.2 $814,538 - $1.01 Million	11,218 Added 2.08%	549,549 $48.2 Million
Q3 2020 Nov 05, 2020	SELL	$71.87 - $131.03 $42.3 Million - $77.2 Million	-589,175 Reduced 52.25%	538,331 $41 Million
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $8.63 Million - $13.5 Million	108,423 Added 10.64%	1,127,506 $139 Million
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $72.7 Million - $98.7 Million	1,019,083 New	1,019,083 $86.1 Million

Others Institutions Holding BMRN

# of Institutions

627

Shares Held

183M

Call Options Held

Put Options Held

1.67M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Biomarin Pharmaceutical Inc Transaction History